industry

A hand-worn device can provide you relief from migraine pain without medicine: Here is how it works, cost



Hyderabad-based pharmaceutical company, Dr Reddy’s Laboratories, has said that it has introduced a groundbreaking wearable therapy device called Nerivio for the treatment of acute migraine. Approved by the US FDA, this non-invasive device is worn on the upper arm and offers a drug-free solution for adults and adolescents aged 12 and above who have been diagnosed with acute migraine, with or without aura.

As per the company, Nerivio, priced at Rs 14,000-16,000, utilizes remote electrical neuromodulation to stimulate nerve endings and activate conditioned pain modulation. This initiates a natural pain-relieving process in the brainstem, resulting in pain inhibition that targets the source of migraine pain in the head. The device, which comes with 18 sessions lasting 45 minutes each, should be used within 60 minutes of the onset of a headache for acute migraine treatment or every alternate day for migraine prevention. Once the 18 sessions are complete, the device should be replaced with a new one.

Controlling the intensity levels of the device is a mobile app that accompanies it. The app also includes an interactive migraine diary to log symptoms, track responses, and provide insightful analytics. Additionally, it features a Guided Imagery, Education, and Relaxation (GIER) protocol that, when used in conjunction with the device, can significantly enhance response rates.

M V Ramana, CEO of Branded Markets (India & Emerging Markets) at Dr Reddy’s, stated that the launch of this device marks the company’s entry into the realm of digital therapeutics. This development follows Dr Reddy’s exclusive agreement with Theranica Bio-electronics, an Israeli digital therapeutics company specializing in advanced neuromodulation devices for migraine and pain management.

Readers Also Like:  DRI initiates probe into parts imports by wind energy companies



READ SOURCE

This website uses cookies. By continuing to use this site, you accept our use of cookies.